Connect with us

Technology

Global Boards Show Progress in Sustainability, But AI and Geopolitical Risks Loom Large, Reports Heidrick & Struggles

Published

on

New global survey by Heidrick & Struggles, BCG, and INSEAD, reveals growing confidence in sustainability governance, but boards and CEOs still lack confidence in each other’s leadership

LONDON, Nov. 19, 2024 /PRNewswire/ — Heidrick & Struggles (Nasdaq: HSII), a premier provider of global leadership advisory and on-demand talent solutions, has teamed with Boston Consulting Group (BCG) and the INSEAD Corporate Governance Centre, to publish a report exploring how boards are responding to complex trends and disruptions they currently face. Boards and Society: How Boards Are Evolving to Meet Challenges from Sustainability to Geopolitical Volatility reveals boards have made meaningful advances to address sustainability topics, but are less confident when it comes to their understanding of other issues such as the rising importance of generative AI, intensifying trade and geopolitical disruptions. These four interconnected pillars are forcing directors and CEOs to navigate an increasingly unpredictable environment filled with conflicting and often politically charged demands.   

Additionally, the report shows evidence of simmering discord among company leadership on how best to enhance competitiveness amid the challenges they face.

Key Findings from the Boardroom

77% of boards believe their company has a responsibility to address sustainability concerns36% feel prepared to leverage the disruptive potential of AI37% believe their company has a sufficient strategy around geopolitical risk29% of directors do not have faith in their CEO to navigate uncertainty26% of CEOs do not have faith in their board’s effectivenessHalf of respondents are not confident their company is equipped to identify new threats and opportunities related to sustainability, generative AI and geopolitics

The report reveals that 77% of the global board members surveyed believe their company has a responsibility to address societal concerns, although more than half (54%) believe that business objectives should remain the primary focus. In contrast to this enthusiasm around sustainability, only 36% of directors feel prepared to leverage the disruptive potential of AI, while just 37% agree that their companies have sufficient strategies in place to manage geopolitical risks.

These findings highlight an urgent need for greater balance between traditional governance with forward-looking strategies and increased investment in board competency. Despite lower levels of confidence for the prevailing risks and emerging technologies of our time, it is encouraging to note that more than 60% of directors stated that their boards are “leaning in” on risk management, suggesting a desire to tackle these challenges head on, regardless of their complexity.

Lack of Confidence Amid Growing Complexity
In a concerning indication of division within the boardroom, the new report reveals that 29% of directors lack confidence in their CEO’s ability to navigate disruption and boost long-term value. Meanwhile, a comparable number of CEOs (26%) are equally skeptical of their board’s effectiveness, reflecting an increasing tension between top leadership teams grappling with a more complex and diverse range of issues than ever before.

The report also finds that roughly half of directors are not confident their company is equipped to identify new threats and opportunities related to sustainability, generative AI and geopolitics, nor are they able translate them into a competitive advantage. As global business landscapes continue to shift, the ability of boards to stay cohesive, align with leadership, and adapt to new challenges with innovative corporate strategy will be more critical than ever. Effective governance that embraces both foresight and resilience will be key in turning these disruptions into opportunities, allowing businesses not only to survive but to thrive in an increasingly volatile world.

Commenting on the findings, Jeremy Hanson, Partner with Heidrick & Struggles and Co-author of the report, commented: “While it is encouraging that boards are stepping up on sustainability, this year’s survey reveals tensions between directors and management regarding each other’s capacity to navigate disruption. With so much at stake—and an increasing complexity to unpack—alignment between board directors and management isn’t just a best practice; it’s essential for addressing both today’s challenges and those of the future. Importantly, alignment does not mean boards should shy away from constructive debate with management. In fact, fostering open, even difficult, conversations is crucial for boards to reach resilient, well-rounded decisions in today’s demanding environment.”

Sonia Tatar, Executive Director of INSEAD Corporate Governance Centre, said, “Boards today can benefit from moving from being reactive to proactive. Beyond understanding disruptions, they can focus on looking ahead—anticipating future shocks and potential risks and finding ways to capitalize on the emerging trends to leverage opportunities. By translating insights that inform decision-making into strategic actions, they will be better positioned to guide companies in becoming more resilient and navigating change effectively.” 

Also commenting on the report, David Young, Managing Director and Senior Partner of BCG added: “Boards are facing new and increasingly complex challenges, amid geopolitical uncertainty, rapid advances in technology, and continued concerns over the impact of climate change. But boards have made notable progress in tackling sustainability–and now there is opportunity for them to learn from these efforts as they engage in deep conversations with executive leadership to confront this expanding agenda.”

Media Inquiries:
Heidrick & Struggles: heidrick@cw8-communications.com
BCG: Gregoire.Eric@bcg.com
INSEAD: news@insead.edu 

About Heidrick & Struggles:
Heidrick & Struggles (Nasdaq: HSII) is a premier provider of global leadership advisory and on-demand talent solutions, serving the senior-level talent and consulting needs of the world’s top organizations. In our role as trusted leadership advisors, we partner with our clients to develop future-ready leaders and organizations, bringing together our services and offerings in executive search, diversity and inclusion, leadership assessment and development, organization and team acceleration, culture shaping and on-demand, independent talent solutions. Heidrick & Struggles pioneered the profession of executive search more than 70 years ago. Today, the firm provides integrated talent and human capital solutions to help our clients change the world, one leadership team at a time. For more, please visit www.heidrick.com

About BCG:
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.

Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.

About INSEAD:
As one of the world’s leading and largest graduate business schools, INSEAD brings together people, cultures, and ideas to develop responsible leaders who transform business and society. Its research, teaching and partnerships reflect this global perspective and cultural diversity.

With locations in EuropeAsia, the Middle East, and North America, INSEAD’s business education and research spans four regions. 159 renowned Faculty members from 41 countries inspire more than 1,500 degree participants annually in the Master in ManagementMBAGlobal Executive MBA, Specialised Master’s degrees (Executive Master in Finance and Executive Master in Change) and PhD programmes. In addition, more than 18,000 executives participate in INSEAD Executive Education programmes each year. 

INSEAD continues to conduct innovative research and innovate across all programmes. The organisation provides business leaders with the knowledge and awareness to operate anywhere. Its core values drive academic excellence and serve the global community as The Business School for the World. For more information, please visit www.insead.edu.

About INSEAD Corporate Governance Centre:
The INSEAD Corporate Governance Centre (ICGC) has been actively engaged in making a distinctive contribution to the knowledge and practice of corporate governance globally. Its vision is to be the leading center for research, innovation, and impact in corporate governance. Through its educational portfolio and advocacy, the ICGC seeks to build greater trust within the public and stakeholder communities, so that businesses are a powerful force for improvement, not only of economic markets but also for the global societal environment. For more, visit www.insead.edu/centres/corporate-governance.

SOURCE Heidrick & Struggles

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Lindus Health Rolls Out “All-in-One Infectious Disease CRO” Bespoke to Clinical Trials for Infectious Disease Interventions

Published

on

By

NEW YORK, Nov. 19, 2024 /PRNewswire/ — Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has introduced their versatile contract research organization (CRO), site, and technology offering tailor-made to the execution of infectious disease trials.

Clinical development of infectious disease treatments and diagnostics must account for complexities such as diverse and evolving pathogens, seasonality and localization of study sites, and enrollment at the appropriate time during infection. Having enrolled over 5,000 patients in infectious disease studies across the US, EU, and UK, Lindus Health is well-equipped to handle the unique challenges within this therapeutic area.

Lindus Health’s latest solution for the infectious disease market segment leverages their full-spectrum CRO and site services, rooted in deep expertise in running infectious disease clinical trials. They are able to recruit diverse study populations at twice the speed of traditional CROs through their expansive recruitment capabilities, including targeted digital outreach campaigns, healthcare and community organization collaborations, and electronic health record (EHR) screening from a repository of over 30 million patients.

“Infectious disease studies require swift and adaptable approaches for execution and recruitment to keep pace with evolving pathogens and public health needs,” said Meri Beckwith, co-founder of Lindus Health. “Therefore speed of execution and access to real-time data are essential, while ensuring enrollment of diverse and representative patient populations.”

The “All-in-One Infectious Disease CRO” offers a comprehensive suite of resources and services to support infectious disease research, including:

Full-service CRO solutions: From protocol writing and study startup to close-out and data delivery, Lindus Health’s clinical operations team oversees all aspects of infectious disease trials, handling all project management and administrative responsibilities.Innovative recruitment strategies: With partnerships across primary care, urgent care, and local community groups as well as EHR screening and direct-to-patient marketing, Lindus employs advanced methods to quickly recruit diverse patient populations in infectious disease studies.Adaptable eClinical software: Citrus™, Lindus’ proprietary clinical research platform custom-built for each trial, stitches together essential tools such as clinical trial management software (CTMS), electronic data capture (EDC), telehealth, and eConsent, providing a true all-in-one solution for cohesive study management.Regulatory and industry insights: Lindus offers expertise on regulatory standards and emerging developments within infectious disease research.Comprehensive site services: Lindus’ site operations team collaborates closely with principal investigators and research staff to execute women’s health trials across single-site, multi-site, hybrid, and fully virtual environments.

“The escalating prevalence and rapid evolution of infectious pathogens present significant challenges to developing interventions to treat, detect, and protect against infectious diseases,” said Dr. Robert Langer, Institute Professor at Massachusetts Institute of Technology and Scientific Advisor to Lindus Health. “With their innovative, agile approaches to trial execution, I believe Lindus Health is well-equipped to quickly adapt and overcome these challenges as they arise.”

Lindus Health is devoted to supporting infectious disease sponsors in bringing groundbreaking treatments and diagnostics to patients and healthcare providers by streamlining all stages of the clinical trial workstream.

To learn more about the “All-in-One Infectious Disease CRO” offering, click here.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved  through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-rolls-out-all-in-one-infectious-disease-cro-bespoke-to-clinical-trials-for-infectious-disease-interventions-302309386.html

SOURCE Lindus Health

Continue Reading

Technology

PI’s New Expansion for Higher Electronics Manufacturing Capacities and Shorter Lead Times

Published

on

By

Investing in the future by improving ergonomics in Rosenheim, Germany facility

AUBURN, Mass., Nov. 19, 2024 /PRNewswire-PRWeb/ — PI, the market and technology leader for high-precision motion control, positioning technology, and piezo applications, has completed the construction of additional electronics production space at its Rosenheim, Germany site.

With investments of around $2.3M and a 30% increase in space, PI is strengthening its global development and production center and the economic development of the region. For 2025, another investment of $2M has been approved.

The expansion will enable production capacities of precision motion control and nanopositioning technology products to be further increased in order to meet the demands of customers from the semiconductor, photonics, laser processing, and life sciences industries.

See a variety of photonics, laser technology, and nanopositioning applications covered by PI system technologies »here.

Industries Served
Photonics, Semiconductors, Laser Technology, Microscopy, Life Sciences

PI Americas
https://www.pi-usa.us | info@pi-usa.us | (508) 832-3456

Applications Blog | Videos | X | LinkedIn

Media Contact

Ceramics Manufacturing Production Expansion, PI (Physik Instrumnente) LP, (508) 832-3456, press-release@pi-usa.us, www.pi-usa.us

Twitter

View original content to download multimedia:https://www.prweb.com/releases/pis-new-expansion-for-higher-electronics-manufacturing-capacities-and-shorter-lead-times-302308759.html

SOURCE PI (Physik Instrumnente) LP; PI (Physik Instrumnente) LP

Continue Reading

Technology

Corteva Agriscience Announces $3 Billion Share Repurchase Program

Published

on

By

Reflects Company’s Focus on Disciplined Capital Deployment

INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ — Corteva, Inc. (NYSE: CTVA) today announced that its Board of Directors authorized a new $3 billion share repurchase program. The authorization is immediately effective, does not expire, and gives management discretion in determining the conditions under which shares may be purchased.

This newly authorized program is in addition to the Company’s existing $2.0 billion program announced in September 2022, which had approximately $750 million remaining as of September 30, 2024. Shares of the Company’s common stock may be repurchased periodically in open-market or private transactions. The actual timing, number and value of shares repurchased under the Company’s authorized share repurchase program will depend on a variety of factors including the market price of Corteva common stock, general market and economic conditions, applicable legal requirements and other business considerations and uses of capital, including organic growth, dividends, and acquisitions.

“This action underscores our Board’s confidence in Corteva’s future and our commitment to returning capital to shareholders,” said Chuck Magro, Chief Executive Officer, Corteva Agriscience. “Corteva’s new share repurchase program, together with the Company’s dividend increase earlier this year, demonstrate Corteva’s strong financial outlook and commitment to a disciplined capital deployment strategy.”

For updates on the Company’s strategy, technology pipeline, and financial framework, join Corteva’s previously announced Investor Day, today at 9 a.m. Eastern Time. Registration is available on the Events and Presentations Page of the Corteva Investor Relations website. A replay will be available on the website following the webcast. 

About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world’s most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Cautionary Statement About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s capital allocation plans, performance outlook, and strategy are forward-looking statements. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent reports on Form 10-Q and Current Reports on Form 8-K.

View original content to download multimedia:https://www.prnewswire.com/news-releases/corteva-agriscience-announces-3-billion-share-repurchase-program-302309807.html

SOURCE Corteva Agriscience

Continue Reading

Trending